Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Progressive liver fibrosis is a major health issue for which no effective treatment is available, leading to cirrhosis and orthotopic liver transplantation. However, organ shortage is a reality. Hence, there is an urgent need to find alternative therapeutic strategies. Cell-based therapy using mesenchymal stem cells (MSCs) may represent an attractive therapeutic option, based on their immunomodulatory properties, their potential to differentiate into hepatocytes, allowing the replacement of damaged hepatocytes, their potential to promote residual hepatocytes regeneration and their capacity to inhibit hepatic stellate cell activation or induce their apoptosis, particularly via paracrine mechanisms. The current review will highlight recent findings regarding the input of MSC-based therapy for the treatment of liver fibrosis, from in vitro studies to pre-clinical and clinical trials. Several studies have shown the ability of MSCs to reduce liver fibrosis and improve liver function. However, despite these promising results, some limitations need to be considered. Future prospects will also be discussed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
The model for end-stage liver disease (MELD)
Kamath, P. S., & Kim, R. W. (2007) · Hepatology · doi:10.1002/hep.21563 · Cited by 1,674
Cited by
PCL-Based Composite Scaffold Matrices for Tissue Engineering Applications
Siddiqui, N., Asawa, S., Birru, B., Baadhe, R., & Rao, S. (2018) · Molecular Biotechnology · doi:10.1007/s12033-018-0084-5 · Cited by 461
Mesenchymal stem cell therapy for liver fibrosis/cirrhosis
Cao, Y., Ji, C., & Lu, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.119 · Cited by 99
“CD4 Th2 cells can promote fibrogenesis by secreting IL-4 and IL-13, while CD4 Th1 cells have an anti-fibrotic effect (70).”
BackgroundNeutrophils alleviate fibrosis in the CCl4-induced mouse chronic liver injury model
Saijou, E., Enomoto, Y., Matsuda, M., Yuet‐Yin Kok, C., Akira, S., Tanaka, M., & Miyajima, A. (2018) · Hepatology Communications · doi:10.1002/hep4.1178 · Cited by 84
“In addition to MSCs from bone marrow, MSCs from other tissues, such as adipose tissue, have been shown to be effective.((28)) However, the mechanism underlying the positive effect of MSCs or macrophages on cirrhosis remains unknown, although several possibilities have been considered; these include transdifferentiatio…”
BackgroundKhalil, M. R., El-Demerdash, R. S., Elminshawy, H. H., Mehanna, E. T., Mesbah, N. M., & Abo-Elmatty, D. M. (2021) · Biomedical Journal · doi:10.1016/j.bj.2020.04.011 · Cited by 29
“BM-MSCs secrete numerous factors, such as nitric oxide and prostaglandin E2 [42], which enhance antioxidant defenses, inhibit oxidation factors, thereby exerting anti-inflammatory effects and reduce necrosis of hepatocytes [43].”
BackgroundHuman umbilical cord mesenchymal stem cells inhibit proliferation of hepatic stellate cells in vitro
Zhang, L.-T., Peng, X.-B., Fang, X.-Q., Li, J.-F., Chen, H., & Mao, X.-R. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3500 · Cited by 29
“HSCs are activated and transformed into muscle fibroblast-like cells, which causes increased synthesis and degradation of collagen (2).”
Background
Metadata
- Authors
- Berardis, S., Dwisthi Sattwika, P., Najimi, M., & Sokal, E. M.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 21
- Issue
- 3
- Pages
- 742
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W1684054028
- Cited by
- 139
- References
- 34
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects. https://app.cochat.ai/papers/10.3748/wjg.v21.i3.742
- The paper
- Berardis, S., Dwisthi Sattwika, P., Najimi, M., & Sokal, E. M. (2015). Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v21.i3.742
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.